Trial Profile
Ulipristal acetate versus conventional management of heavy menstrual bleeding (HMB; including uterine fibroids): a randomised controlled trial and exploration of mechanism of action (UCON trial)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 31 May 2022
Price :
$35
*
At a glance
- Drugs Ulipristal (Primary) ; Levonorgestrel
- Indications Menstruation disorders
- Focus Therapeutic Use
- Acronyms UCON
- 14 Apr 2021 Results (n=16) of a cross-sectional study obtained endometrial biopsies samples from this study assessing impact of the progesterone receptor modulator, ulipristal acetate, on endometrial morphology and function published in the Fertility and Sterility
- 21 May 2020 Planned End Date changed from 30 Sep 2018 to 31 May 2021.
- 21 May 2020 Status changed to active, no longer recruiting.